摘要
目前宫颈癌的发病率仍居全世界妇女常见恶性肿瘤的第二位.高危型人乳头瘤病毒（high-risk Human Papillomavirus,HR-HPV）感染是宫颈癌及其癌前病变最主要的诱因之一.抑癌基因p53能够有效地抑制细胞增殖和促进细胞凋亡,人类近半数的肿瘤都与p53基因的突变和失活有关,HPV E6蛋白降解p53蛋白,是宫颈癌发生的前提.选择性杀伤p53功能缺失的肿瘤细胞,同时保护正常细胞,发展HPV疫苗及联合用药是临床肿瘤免疫学家进行宫颈癌基因治疗的目标.
Cervical cancer is still the second most common malignancy in women worldwide. The high - risk HPV（ human papilloma virus） has been found to be the main cause of the majority of cervical cancers and its precursor lesions, p53 tumor suppressor gene can inhibit cell proliferation and promote apoptosis effectively. Near- ly half of human tumors are associated with mutation and inactivation of p53 gene p53 protein degradation by HPV E6 protein is a precondition for cervical cancers. To selectively kill the p53 function - losing tumor cells while protecting the normal cells and to develop HPV vaccines, and the combination using of medicines are the cervical cancer gene therapy goals for clinical immunologist.
出处
《实用肿瘤学杂志》
CAS
2011年第6期588-592,共5页
Practical Oncology Journal
关键词
P53
HPV
E6
宫颈癌
基因治疗
p53
Human papilloma virus E6
Cervical carcinoma
Gene therapy
